
|Videos|March 1, 2017
A Subgroup Analysis of the FALCON Trial for HR+ Breast Cancer
Author(s)John Robertson, MD
John Robertson, MD, professor of Surgery, University of Nottingham, Royal Derby Hospital Centre, United Kingdom, discusses a subgroup analysis of the FALCON trial, which compared treatment with fulvestrant versus anastrozole in patients with HR-positive advanced breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5










































